Your Article Summary
See Latest ArticlesTakeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Takeda Pharmaceuticals North America, 07/02/09
Takeda Pharmaceutical Company Limited announced that Takeda Global Research and Development Center, Inc., a wholly owned United States subsidiary received on June 26 a complete response letter from the U.S. Food and Drug Administration regarding the Company's New Drug Application for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09
Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09
Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
Bristol Myers-Squibb Company, 12/07/09